Table 4 Incremental cost-effectiveness ratios (ICERs) and probabilities of each intervention being the most cost effective at various willingness-to-pay thresholds
Intervention | Meta-analysis | ICER | Probability of being cost-effective by willingness-to-pay threshold | |||
|---|---|---|---|---|---|---|
$30,000/QALY | $50,000/QALY | $70,000/QALY | $100,000/QALY | |||
Placebo as reference | ||||||
Placebo | PTC | Reference | 35% | 10% | 3% | 0% |
MTC | Reference | 37% | 12% | 3% | 2% | |
ICS | PTC | 27044 | 40% | 42% | 38% | 31% |
MTC | 27614 | 49% | 55% | 44% | 31% | |
LABA | PTC | 65509 | 1% | 6% | 6% | 5% |
MTC | 64339 | 1% | 2% | 1% | 0% | |
ICS + LABA | PTC | 57933 | 1% | 6% | 11% | 18% |
MTC | 52116 | 0% | 7% | 1% | 29% | |
LAMA | PTC | 38427 | 21% | 34% | 43% | 46% |
MTC | 41203 | 13% | 24% | 35% | 38% | |
ICS as reference | ||||||
LABA | PTC | Dominated | -- | -- | -- | -- |
| Â | MTC | Dominated | -- | -- | -- | -- |
ICS + LABA | PTC | 89843 | -- | -- | -- | -- |
| Â | MTC | 96749 | -- | -- | -- | -- |
LAMA | PTC | 25930 | -- | -- | -- | -- |
| Â | MTC | 57854 | -- | -- | -- | -- |